Document:

EX-10.1

 Exhibit 10.1 

INDEMNITY AGREEMENT 

THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of
            , 20    , is made by and between DECIPHER BIOSCIENCES, INC., a Delaware corporation (the
“Company”), and                      (“Indemnitee”). 

RECITALS 

A.    The Company desires to attract and retain the services of highly qualified individuals as directors,
officers, employees and agents. 
 B.    The Company’s Amended and Restated Bylaws (the
“Bylaws”) require that the Company indemnify its directors and officers, and empowers the Company to indemnify its employees and other agents, as authorized by the Delaware General Corporation Law, as amended (the
“Code”), under which the Company is organized and such Bylaws expressly provide that the indemnification provided therein is not exclusive and contemplates that the Company may enter into separate agreements with its
directors, officers and other persons to set forth specific indemnification provisions. 
 C.    Indemnitee does
not regard the protection currently provided by applicable law, the Bylaws, the Company’s other governing documents, and available insurance as adequate under the present circumstances, and the Company has determined that Indemnitee and other
directors, officers, employees and agents of the Company may not be willing to serve or continue to serve in such capacities without additional protection. 

D.    The Company desires and has requested Indemnitee to serve or continue to serve as a director, officer,
employee or agent of the Company, as the case may be, and has proffered this Agreement to Indemnitee as an additional inducement to serve in such capacity. 

E.    Indemnitee is willing to serve, or to continue to serve, as a director, officer, employee or agent of the
Company, as the case may be, if Indemnitee is furnished the indemnity provided for herein by the Company. 
 AGREEMENT

 NOW THEREFORE, in consideration of the mutual covenants and agreements set forth
herein, the parties hereto, intending to be legally bound, hereby agree as follows: 
 1.    Definitions.

 (a)    Agent. For purposes of this Agreement, the term “Agent” of the Company
means any person who: (i) is or was a director, officer, employee, agent, or other fiduciary of the Company or a subsidiary of the Company; or (ii) is or was serving at the request or for the convenience of, or representing the
interests of, the Company or a subsidiary of the Company, as a director, officer, employee, agent, or other fiduciary of a foreign or domestic corporation, partnership, joint venture, trust or other enterprise. 

  
 1. 

 (b)    Change in Control. For purposes of this Agreement,
a “Change in Control” shall be deemed to have occurred if (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), other than a trustee or other fiduciary holding securities under an employee benefit plan of the Company or a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as
their ownership of stock of the Company, is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 20%
or more of the total voting power represented by the Company’s then outstanding Voting Securities, (ii) individuals who on the date of this Agreement are members of the Board (the “Incumbent Board”) cease for any
reason to constitute at least a majority of the members of the Board (provided, however, that if the appointment or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members of
the Incumbent Board then still in office, such new member shall be considered as a member of the Incumbent Board), or (iii) the stockholders of the Company approve a merger or consolidation of the Company with any other corporation, other than
a merger or consolidation which would result in the Voting Securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into Voting Securities of the surviving entity)
at least 80% of the total voting power represented by the Voting Securities of the Company or such surviving entity outstanding immediately after such merger or consolidation, or the stockholders of the Company approve a plan of complete liquidation
of the Company or an agreement for the sale or disposition by the Company of (in one transaction or a series of transactions) all or substantially all of the Company’s assets. 

(c)    Expenses. For purposes of this Agreement, the term “Expenses” shall be
broadly construed and shall include, without limitation, all direct and indirect costs of any type or nature whatsoever, including, without limitation, all attorneys’, witness, or other professional fees and related disbursements, and other out-of-pocket costs of whatever nature, actually and reasonably incurred by Indemnitee in connection with the investigation, defense or appeal of a proceeding or establishing
or enforcing a right to indemnification under this Agreement, the Code or otherwise. The term “Expenses” shall also include reasonable compensation for time spent by Indemnitee for which he or she is not compensated by the
Company or any subsidiary or third party: (i) for any period during which Indemnitee is not an Agent, in the employment of, or providing services for compensation to, the Company or any subsidiary; and (ii) if the rate of compensation and
estimated time involved is approved by the directors of the Company who are not parties to any action with respect to which Expenses are incurred, for Indemnitee while an Agent of, employed by, or providing services for compensation to, the Company
or any subsidiary. 
 (d)    Independent Counsel. For purposes of this Agreement, the term
“Independent Counsel” means a law firm, or a partner (or, if applicable, member) of such a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five (5) years has
been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party, or (ii) any other party to the proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term
“Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action
to determine Indemnitee’s rights under this Agreement. The Company will pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all expenses, claims, liabilities and
damages arising out of or relating to this Agreement or its engagement pursuant hereto. 

  
 2. 

 (e)    Liabilities. For purposes of this Agreement, the
term “Liabilities” shall be broadly construed and shall include, without limitation, judgments, damages, deficiencies, liabilities, losses, penalties, excise taxes, fines, assessments and amounts paid in settlement, including
any interest and any federal, state, local or foreign taxes imposed as a result of the actual or deemed receipt of any payment under this Agreement. 

(f)    Proceedings. For purposes of this Agreement, the term “proceeding” shall be
broadly construed and shall include, without limitation, any threatened, pending, or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative
hearing, or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative or investigative nature, and whether formal or informal in any case, in which
Indemnitee was, is or will be involved as a party, potential party, non-party witness, or otherwise by reason of: (i) the fact that Indemnitee is or was a director or officer of the Company; (ii) the
fact that any action taken by Indemnitee (or a failure to take action by Indemnitee) or of any action (or failure to act) on Indemnitee’s part while acting as an Agent; or (iii) the fact that Indemnitee is or was serving at the request of
the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan, or other enterprise, and in any such case described above, whether or not serving in any such capacity at the
time any liability or Expense is incurred for which indemnification, reimbursement, or advancement of Expenses may be provided under this Agreement. If the Indemnitee believes in good faith that a given situation may lead to or culminate in the
institution of a proceeding, this shall be considered a proceeding under this paragraph. 

(g)    Subsidiary. For purposes of this Agreement, the term “subsidiary” means any
corporation, limited liability company, or other entity, of which more than 50% of the outstanding voting securities or equity interests are owned, directly or indirectly, by the Company and one or more of its subsidiaries, and any other
corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as an Agent. 

(h)    Voting Securities. For purposes of this Agreement, “Voting Securities” shall
mean any securities of the Company that vote generally in the election of directors. 
 2.    Agreement to
Serve. Indemnitee will serve, or continue to serve, as the case may be, as an Agent, faithfully and to the best of his or her ability, at the will of such entity designated by the Company and at the request of the Company (or under separate
agreement, if such agreement exists), in the capacity Indemnitee currently serves such entity, so long as Indemnitee is duly appointed or elected and qualified in accordance with the applicable provisions of the governance documents of such entity,
or until such time as Indemnitee tenders his or her resignation in writing; provided, however, that nothing contained in this Agreement is intended as an employment agreement between Indemnitee and the Company or any of its subsidiaries or to create
any right to continued employment of Indemnitee with the Company or any of its subsidiaries in any capacity. 

  
 3. 

 The Company acknowledges that it has entered into this Agreement and assumes the obligations
imposed on it hereby, in addition to and separate from its obligations to Indemnitee under the Bylaws, to induce Indemnitee to serve, or continue to serve, as an Agent, and the Company acknowledges that Indemnitee is relying upon this Agreement in
serving as an Agent. 
 3.    Indemnification. 

(a)    Indemnification in Third Party Proceedings. Subject to Section 10 below, the Company shall
indemnify Indemnitee to the fullest extent permitted by the Code, as the same may be amended from time to time (but, to the fullest extent of the law, only to the extent that such amendment permits Indemnitee to broader indemnification rights than
the Code permitted prior to adoption of such amendment), if Indemnitee is a party to or threatened to be made a party to or otherwise involved in any proceeding, other than a proceeding by or in the right of the Company to procure a judgment in its
favor, for any and all Expenses and Liabilities (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses and Liabilities) incurred by Indemnitee in connection with the investigation,
defense, settlement or appeal of such proceeding, if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding had no
reasonable cause to believe that Indemnitee’s conduct was unlawful. The parties hereto intend that this Agreement shall provide to the fullest extent permitted by law for indemnification in excess of that expressly permitted by statute,
including, without limitation, any indemnification provided by the Certificate of Incorporation of the Company, the Bylaws, vote of its stockholders or disinterested directors, or applicable law. 

(b)    Indemnification in Derivative Actions and Direct Actions by the Company. Subject to Section 10
below, the Company shall indemnify Indemnitee to the fullest extent permitted by the Code, as the same may be amended from time to time (but, fullest extent permitted by applicable law, only to the extent that such amendment permits Indemnitee to
broader indemnification rights than the Code permitted prior to adoption of such amendment), if Indemnitee is a party to or threatened to be made a party to or otherwise involved in any proceeding by or in the right of the Company to procure a
judgment in its favor, against any and all Expenses actually and reasonably incurred by Indemnitee in connection with the investigation, defense, settlement, or appeal of such proceedings, if Indemnitee acted in good faith and in a manner Indemnitee
reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section 3(b) in respect of any claim, issue or matter as to which Indemnitee shall have been finally
adjudged by a court competent jurisdiction to be liable to the Company, unless and only to the extent that the Chancery Court of the State of Delaware or any court in which the proceeding was brought shall determine upon application that, despite
the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification. 

4.    Indemnification of Expenses of Successful Party. Notwithstanding any other provision of this
Agreement, in circumstances where indemnification is not available under Section 3(a) or 3(b), as the case may be, to the fullest extent permitted by law and to the extent that Indemnitee is a party to (or a participant in) any proceeding and
has been successful on the merits or otherwise in defense of any proceeding or in defense of any claim, issue or matter therein, 

  
 4. 

 
in whole or part, including the dismissal of any action without prejudice, the Company shall indemnify Indemnitee against all Expenses and Liabilities in connection with the investigation,
defense or appeal of such proceeding. If Indemnitee is not wholly successful in such proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such proceeding, the Company shall
indemnify Indemnitee against all Expenses and Liabilities incurred by Indemnitee or on Indemnitee’s behalf in connection with or related to each successfully resolved claim, issue or matter to the fullest extent permitted by law. 

5.    Partial Indemnification; Witness Indemnification. If Indemnitee is entitled under any provision of
this Agreement to indemnification by the Company for some or a portion of any Expenses and Liabilities incurred by Indemnitee in the investigation, defense, settlement or appeal of a proceeding, but is precluded by applicable law or the specific
terms of this Agreement to indemnification for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled. Notwithstanding any other provision of this Agreement, to the
fullest extent permitted by applicable law and to the extent that Indemnitee is, by reason of Indemnitee’s acting as an Agent, a witness or otherwise asked to participate in any proceeding to which Indemnitee is not a party, Indemnitee shall be
indemnified against all Expenses incurred by Indemnitee or on Indemnitee’s behalf in connection therewith. 

6.    Advancement of Expenses. To the extent not prohibited by law, the Company shall advance the Expenses
incurred by Indemnitee in connection with any proceeding, and such advancement shall be made within twenty (20) days after the receipt by the Company of a statement or statements requesting such advances (which shall include invoices received
by Indemnitee in connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable
law shall not be included with the invoice) and upon request of the Company, an undertaking to repay the advancement of Expenses if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not
subject to appeal, that Indemnitee is not entitled to be indemnified by the Company. Advances shall be unsecured, interest free and without regard to Indemnitee’s ability to repay the Expenses. Advances shall include any and all Expenses
incurred by Indemnitee pursuing an action to enforce Indemnitee’s right to indemnification under this Agreement or otherwise and this right of advancement, including expenses incurred preparing and forwarding statements to the Company to
support the advances claimed. Indemnitee acknowledges that the execution and delivery of this Agreement shall constitute an undertaking providing that Indemnitee shall, to the fullest extent required by law, repay the advance (without interest) if
and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the Company. The right to advances under this Section shall
continue until final disposition of any proceeding, including any appeal therein. This Section 6 shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 10(b). 

7.    Notice and Other Indemnification Procedures. 

(a)    Notification of Proceeding. Indemnitee will notify the Company in writing promptly upon being served
with any summons, citation, subpoena, complaint, indictment, information or other document relating to any proceeding or matter which may be subject to 

  
 5. 

 
indemnification or advancement of Expenses covered hereunder. The written notification to the Company shall include a description of the nature of the proceeding and the facts underlying the
proceeding. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise and any delay in so notifying the Company shall not constitute a waiver
by Indemnitee of any rights under this Agreement. 
 (b)    Request for Indemnification Payments. To
obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to
determine whether and to what extent Indemnitee is entitled to indemnification under the terms of this Agreement, and shall request payment thereof by the Company. 

(c)    Determination of Right to Indemnification Payments. Upon written request by Indemnitee for
indemnification pursuant to the Section 7(b) hereof, a determination with respect to Indemnitee’s entitlement thereto shall be made in the specific case by one of the following four methods, which shall be at the election of the Board of
Directors: (1) by a majority vote of the disinterested directors, even though less than a quorum, (2) by a committee of disinterested directors designated by a majority vote of the disinterested directors, even though less than a quorum,
(3) if there are no disinterested directors or if the disinterested directors so direct, by Independent Counsel in a written opinion to the Board of Directors, a copy of which shall be delivered to the Indemnitee, or (4) if so directed by
the Board of Directors, by the stockholders of the Company; provided, however, that if there has been a Change in Control, then such determination shall be made by Independent Counsel selected by Indemnitee and approved by the Company (which
approval shall not be unreasonably withheld). For purposes hereof, disinterested directors are those members of the board of directors of the Company who are not parties to the action, suit or proceeding in respect of which indemnification is sought
by Indemnitee. Indemnification payments requested by Indemnitee under Section 3 hereof shall be made by the Company no later than sixty (60) days after receipt of the written request of Indemnitee. Claims for advancement of Expenses shall
be made under the provisions of Section 6 herein. 
 (d)    Application for Enforcement. In the event
the Company fails to make timely payments as set forth in Sections 6 or 7(b) above, Indemnitee shall have the right to apply to any court of competent jurisdiction for the purpose of enforcing Indemnitee’s right to indemnification or
advancement of Expenses pursuant to this Agreement. In such an enforcement hearing or proceeding, the burden of proof shall be on the Company to prove that indemnification or advancement of Expenses to Indemnitee is not required under this Agreement
or permitted by applicable law. Any determination by the Company (including its Board of Directors, a committee thereof, Independent Counsel) or stockholders of the Company, that Indemnitee is not entitled to indemnification hereunder, shall not be
a defense by the Company to the action nor create any presumption that Indemnitee is not entitled to indemnification or advancement of Expenses hereunder. 

(e)    Indemnification of Certain Expenses. The Company shall indemnify Indemnitee against all Expenses
incurred in connection with any hearing or proceeding under this Section 7 unless the Company prevails in such hearing or proceeding on the merits in all material respects. 

  
 6. 

 8.    Assumption of Defense. In the event the Company
shall be requested by Indemnitee to pay the Expenses of any proceeding, the Company, if appropriate, shall be entitled to assume the defense of such proceeding, or to participate to the extent permissible in such proceeding, with counsel reasonably
acceptable to Indemnitee. Upon assumption of the defense by the Company and the retention of such counsel by the Company, the Company shall not be liable to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee
with respect to the same proceeding, provided that Indemnitee shall have the right to employ separate counsel in such proceeding at Indemnitee’s sole cost and expense. Notwithstanding the foregoing, if Indemnitee’s counsel delivers a
written notice to the Company stating that such counsel has reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of any such defense or the Company shall not, in fact, have employed counsel
or otherwise actively pursued the defense of such proceeding within a reasonable time, then in any such event the fees and Expenses of Indemnitee’s counsel to defend such proceeding shall be subject to the indemnification and advancement of
Expenses provisions of this Agreement. 
 9.    Insurance. To the extent that the Company maintains an
insurance policy or policies providing liability insurance for Agents (“D&O Insurance”), Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage
available for any such Agent under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has D&O Insurance in effect or otherwise potentially available, the Company shall give
prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf
of Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies. 

10.    Exceptions. 

(a)    Certain Matters. Any provision herein to the contrary notwithstanding, the Company shall not be
obligated pursuant to the terms of this Agreement to indemnify Indemnitee on account of any proceeding with respect to: (i) remuneration paid to Indemnitee if it is determined by final judgment or other final adjudication that such remuneration
was in violation of law (and, in this respect, both the Company and Indemnitee have been advised that the Securities and Exchange Commission believes that indemnification for liabilities arising under the federal securities laws is against public
policy and is, therefore, unenforceable and that claims for indemnification should be submitted to appropriate courts for adjudication, as indicated in Section 10(d) below); (ii) a final judgment rendered against Indemnitee for an
accounting, disgorgement or repayment of profits made from the purchase or sale by Indemnitee of securities of the Company against Indemnitee or in connection with a settlement by or on behalf of Indemnitee to the extent it is acknowledged by
Indemnitee and the Company that such amount paid in settlement resulted from Indemnitee’s conduct from which Indemnitee received monetary personal profit, pursuant to the provisions of Section 16(b) of the Exchange Act or other provisions
of any federal, state or local statute or rules and regulations thereunder; (iii) a final judgment or other final adjudication 

  
 7. 

 
that Indemnitee’s conduct was in bad faith, knowingly fraudulent or deliberately dishonest or constituted willful misconduct (but only to the extent of such specific determination); or
(iv) on account of conduct that is established by a final judgment as constituting a breach of Indemnitee’s duty of loyalty to the Company or resulting in any personal profit or advantage to which Indemnitee is not legally entitled. For
purposes of the foregoing sentence, a final judgment or other adjudication may be reached in either the underlying proceeding or action in connection with which indemnification is sought or a separate proceeding or action to establish rights and
liabilities under this Agreement. 
 (b)    Claims Initiated by Indemnitee. Any provision herein to the
contrary notwithstanding, the Company shall not be obligated to indemnify or advance Expenses to Indemnitee with respect to proceedings or claims initiated or brought by Indemnitee against the Company or its Agents and not by way of defense, except
(i) with respect to proceedings brought to establish or enforce a right to indemnification or advancement under this Agreement or under any other agreement, provision in the Bylaws or the Certificate of Incorporation or applicable law, or
(ii) with respect to any other proceeding initiated by Indemnitee that is either approved by the Board of Directors or Indemnitee’s participation is required by applicable law. However, indemnification or advancement of Expenses may be
provided by the Company in specific cases if the Board of Directors determines it to be appropriate. 

(c)    Unauthorized Settlements. Any provision herein to the contrary notwithstanding, the Company shall not
be obligated pursuant to the terms of this Agreement to indemnify Indemnitee under this Agreement for any amounts paid in settlement of a proceeding effected without the Company’s written consent. Neither the Company nor Indemnitee shall
unreasonably withhold consent to any proposed settlement; provided, however, that the Company may in any event decline to consent to (or to otherwise admit or agree to any liability for indemnification hereunder in respect of) any proposed
settlement if the Company is also a party in such proceeding and determines in good faith that such settlement is not in the best interests of the Company and its stockholders. 

(d)    Securities Act Liabilities. Any provision herein to the contrary notwithstanding, the Company shall
not be obligated pursuant to the terms of this Agreement to indemnify Indemnitee or otherwise act in violation of any undertaking appearing in and required by the rules and regulations promulgated under the Securities Act of 1933, as amended (the
“Securities Act”), or in any registration statement filed with the SEC under the Securities Act. Indemnitee acknowledges that paragraph (h) of Item 512 of Regulation
S-K currently generally requires the Company to undertake in connection with any registration statement filed under the Securities Act to submit the issue of the enforceability of Indemnitee’s rights
under this Agreement in connection with any liability under the Securities Act on public policy grounds to a court of appropriate jurisdiction and to be governed by any final adjudication of such issue. Indemnitee specifically agrees that any such
undertaking shall supersede the provisions of this Agreement and to be bound by any such undertaking. 

(e)    Prior Payments Any provision herein to the contrary notwithstanding, the Company shall not be
obligated pursuant to the terms of this Agreement to indemnify or advance Expenses to Indemnitee under this Agreement for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision,
expect with respect to any excess beyond the amount paid under any insurance policy or indemnity policy. 

  
 8. 

 11.    Nonexclusivity and Survival of Rights. The
provisions for indemnification and advancement of Expenses set forth in this Agreement shall not be deemed exclusive of any other rights which Indemnitee may at any time be entitled under any provision of applicable law, the Company’s
Certificate of Incorporation, the Bylaws or other agreements, both as to action in Indemnitee’s official capacity and Indemnitee’s action as an Agent, in any court in which a proceeding is brought, and Indemnitee’s rights hereunder
shall continue after Indemnitee has ceased acting as an Agent and shall inure to the benefit of the heirs, executors, administrators and assigns of Indemnitee. The obligations and duties of the Company to Indemnitee under this Agreement shall be
binding on the Company and its successors and assigns until terminated in accordance with its terms. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of
the business or assets of the Company, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place. 

No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this
Agreement in respect of any action taken or omitted by such Indemnitee in his or her corporate status prior to such amendment, alteration or repeal. To the extent that a change in the Code, whether by statute or judicial decision, permits greater
indemnification or advancement of Expenses than would be afforded currently under the Company’s Certificate of Incorporation, the Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement
the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given
hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, by Indemnitee shall not prevent the concurrent assertion or employment of any other right or remedy
by Indemnitee. 
 12.    Term. This Agreement shall continue until and terminate upon the later of:
(a) five (5) years after the date that Indemnitee shall have ceased to serve as an Agent; or (b) one (1) year after the final termination of any proceeding, including any appeal then pending, in respect to which Indemnitee was granted
rights of indemnification or advancement of Expenses hereunder. 
 No legal action shall be brought and no cause of action shall be asserted
by or in the right of the Company against an Indemnitee or an Indemnitee’s estate, spouse, heirs, executors or personal or legal representatives after the expiration of five (5) years from the date of accrual of such cause of action, and
any claim or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such five-year period; provided, however, that if any shorter period of limitations is otherwise
applicable to such cause of action, such shorter period shall govern. 
 13.    [To be included if
applicable:] Primacy of Indemnification. The Company hereby acknowledges that Indemnitee has certain rights to indemnification, advancement of expenses and/or insurance provided by [Name of Fund/Sponsor] and certain of [its][their]
affiliates 

  
 9. 

 
(collectively, the “Fund Indemnitors”). The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to Indemnitee are primary
and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be required to advance the full amount of expenses incurred
by Indemnitee and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement and the Certificate of Incorporation or
Bylaws of the Company (or any other agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Fund Indemnitors, and (iii) that it irrevocably waives, relinquishes and releases the Fund
Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of
Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or
payment to all of the rights of recovery of Indemnitee against the Company. The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of the terms of this Section 13. 

14.    Subrogation. In the event of payment under this Agreement, the Company shall be subrogated to the
extent of such payment to all of the rights of recovery of Indemnitee, who, at the request and expense of the Company, shall execute all papers required and shall do everything that may be reasonably necessary to secure such rights, including the
execution of such documents necessary to enable the Company effectively to bring suit to enforce such rights. 

15.    Interpretation of Agreement. It is understood that the parties hereto intend this Agreement to be
interpreted and enforced so as to provide indemnification and advancement of Expenses to Indemnitee to the fullest extent now or hereafter permitted by law. 

16.    Severability. If any provision of this Agreement shall be held to be invalid, illegal or
unenforceable for any reason whatsoever, (a) the validity, legality and enforceability of the remaining provisions of the Agreement (including without limitation, all portions of any paragraphs of this Agreement containing any such provision
held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this Agreement (including,
without limitation, all portions of any paragraph of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall be construed so as to give effect to the
intent manifested by the provision held invalid, illegal or unenforceable and to give effect to Section [14 / 15] hereof. 

17.    Amendment and Waiver. No supplement, modification, amendment, or cancellation of this Agreement shall
be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not similar) nor shall such waiver constitute a
continuing waiver. 
 18.    Notice. Except as otherwise provided herein, any notice or demand which, by
the provisions hereof, is required or which may be given to or served upon the parties hereto shall be 

  
 10. 

 
in writing and, if by electronic transmission, shall be deemed to have been validly served, given or delivered when sent, if by overnight delivery, courier or personal delivery, shall be deemed
to have been validly served, given or delivered upon actual delivery and, if mailed, shall be deemed to have been validly served, given or delivered three (3) business days after deposit in the United States mail, as registered or certified
mail, with proper postage prepaid and addressed to the party or parties to be notified at the addresses set forth on the signature page of this Agreement (or such other address(es) as a party may designate for itself by like notice). If to the
Company, notices and demands shall be delivered to the attention of the Secretary of the Company. 

19.    Governing Law. This Agreement shall be governed exclusively by and construed according to the laws of
the State of Delaware, as applied to contracts between Delaware residents entered into and to be performed entirely within Delaware. 

20.    Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all
purposes be deemed to be an original but all of which together shall constitute but one and the same Agreement. Only one such counterpart need be produced to evidence the existence of this Agreement. 

21.    Headings. The headings of the sections of this Agreement are inserted for convenience only and shall
not be deemed to constitute part of this Agreement or to affect the construction hereof. 
 22.    Entire
Agreement. Subject to Section 11 hereof, this Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings and negotiations, written and oral,
between the parties with respect to the subject matter of this Agreement; provided, however, that this Agreement is a supplement to and in furtherance of the Company’s Certificate of Incorporation, the Bylaws, the Code and any other applicable
law, and shall not be deemed a substitute therefor, and does not diminish or abrogate any rights of Indemnitee thereunder. 

23.    Contribution. To the fullest extent permissible under applicable law, if the indemnification provided
for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid
or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such proceeding in
order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such proceeding; and/or (ii) the relative fault of the Company and Indemnitee in connection
with such event(s) and/or transaction(s). 
 24.    Consent to Jurisdiction. The Company and Indemnitee
hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware (the “Delaware
Court”), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or
proceeding arising out of or in connection with this Agreement, 

  
 11. 

 
(iii) agree to appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, an agent in the State of Delaware as such party’s agent for
acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying
of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.

  
 12. 

 IN WITNESS WHEREOF, the
parties hereto have entered into this Agreement effective as of the date first above written. 
  

					
	DECIPHER BIOSCIENCES, INC.
		
	By:	 	  

		 	Name:	 	  

		 	Title:	 	  

	
	INDEMNITEE
	
	  

	Signature of Indemnitee
	
	  

	Print or Type Name of IndemniteeEX-10.2

 Exhibit 10.2 

GENOMEDX BIOSCIENCES INC. 

2011 
 AMENDED STOCK
OPTION PLAN 
 Approved by the Board on December 2, 2011. Amendments approved by the Board on September 18, 2013, January 14, 2016,
August 16, 2016, March 16, 2017 and March 20, 2018. 
  

 TABLE OF CONTENTS 

 

							
	 ARTICLE 1 DEFINITIONS AND INTERPRETATION
	  	 	1	 
			
	 1.1
	  	Definitions	  	 	1	 
	 1.2
	  	Choice of Law	  	 	4	 
	 1.3
	  	Headings	  	 	4	 
		
	 ARTICLE 2 PURPOSE AND PARTICIPATION
	  	 	4	 
			
	 2.1
	  	Purpose	  	 	4	 
	 2.2
	  	Participation	  	 	4	 
	 2.3
	  	Notification of Award	  	 	4	 
	 2.4
	  	Copy of Plan	  	 	4	 
	 2.5
	  	Limitation	  	 	4	 
		
	 ARTICLE 3 TERMS AND CONDITIONS OF OPTIONS
	  	 	5	 
			
	 3.1
	  	Board to Issue Common Shares	  	 	5	 
	 3.2
	  	Number of Common Shares	  	 	5	 
	 3.3
	  	Term of Option	  	 	5	 
	 3.4
	  	Termination	  	 	5	 
	 3.5
	  	Exercise Price	  	 	8	 
	 3.6
	  	Additional Terms	  	 	9	 
	 3.7
	  	Going Public Agreements	  	 	9	 
	 3.8
	  	Assignment of Options	  	 	9	 
	 3.9
	  	Adjustments	  	 	10	 
	 3.10
	  	Option Grant and Vesting Terms	  	 	10	 
	 3.11
	  	U.S. Participants	  	 	10	 
		
	 ARTICLE 4 EXERCISE OF OPTION
	  	 	11	 
			
	 4.1
	  	Exercise of Option	  	 	11	 
	 4.2
	  	Shareholder’s Agreement	  	 	11	 
	 4.3
	  	Execution of Shareholder’s Agreement	  	 	11	 
	 4.4
	  	Issue of Share Certificates	  	 	12	 
	 4.5
	  	Condition of Issue	  	 	12	 
		
	 ARTICLE 5 ADMINISTRATION
	  	 	12	 
			
	 5.1
	  	Administration	  	 	12	 
	 5.2
	  	Interpretation	  	 	12	 
		
	 ARTICLE 6 AMENDMENT, TERMINATION AND NOTICE
	  	 	12	 
			
	 6.1
	  	Prospective Amendment	  	 	12	 

  
 i 

							
	 6.2
	  	Retrospective Amendment	  	 	13	 
	 6.3
	  	Approvals	  	 	13	 
	 6.4
	  	Termination	  	 	13	 
	 6.5
	  	Agreement	  	 	13	 
	 6.6
	  	Notice	  	 	13	 
		
	 SCHEDULE A
	  	 	A-1	 
		
	 SCHEDULE B
	  	 	B-1	 
		
	 SCHEDULE C
	  	 	C-1	 
		
	 ARTICLE 1 INTERPRETATION
	  	 	C-1	 
			
	 1.1
	  	Definitions	  	 	C-1	 
	 1.2
	  	Words	  	 	C-3	 
	 1.3
	  	Headings	  	 	C-3	 
		
	 ARTICLE 2 SCOPE, EFFECT AND PARTIES
	  	 	C-4	 
			
	 2.1
	  	Shareholder to Act in Support of Terms	  	 	C-4	 
	 2.2
	  	Terms to Prevail over Constating Documents	  	 	C-4	 
	 2.3
	  	Ceasing to be a Party	  	 	C-4	 
	 2.4
	  	Termination of Agreement	  	 	C-4	 
	 2.5
	  	Amendment of Agreement	  	 	C-4	 
		
	 ARTICLE 3 SHARE TRANSFERS
	  	 	C-4	 
			
	 3.1
	  	Transfers Restricted	  	 	C-4	 
	 3.2
	  	Permitted Transfers	  	 	C-4	 
	 3.3
	  	Right of First Refusal	  	 	C-5	 
	 3.4
	  	Drag-Along Right	  	 	C-6	 
	 3.5
	  	Company’s Option to Repurchase Shareholder’s Shares	  	 	C-7	 
	 3.6
	  	Going Public Agreements	  	 	C-7	 
	 3.7
	  	Recognition of Transfers	  	 	C-8	 
	 3.8
	  	Endorsement on Share Certificates	  	 	C-8	 
		
	 ARTICLE 4 GENERAL PROVISIONS
	  	 	C-8	 
			
	 4.1
	  	No Partnership	  	 	C-8	 
	 4.2
	  	Time of the Essence	  	 	C-8	 
	 4.3
	  	Further Acts	  	 	C-8	 
	 4.4
	  	Parties of Interest	  	 	C-8	 
	 4.5
	  	Share Reorganizations	  	 	C-8	 
	 4.6
	  	Governing Law	  	 	C-9	 
	 4.7
	  	Entire Agreement	  	 	C-9	 
	 4.8
	  	Notices	  	 	C-9	 

  
 ii 

							
	 4.9
	  	Waiver	  	 	C-9	 
	 4.10
	  	Severability	  	 	C-9	 
	 4.11
	  	Assignment	  	 	C-9	 
	 4.12
	  	Arbitration	  	 	C-10	 
	 4.13
	  	Counterparts	  	 	C-10	 

  
 iii 

 AMENDED STOCK OPTION PLAN 

ARTICLE 1 

DEFINITIONS AND INTERPRETATION 
  

	1.1	 Definitions 

As used herein, unless there is something in the subject matter or context inconsistent therewith, the following terms will have the meanings set forth below:

  

	 	(a)	 “Administrator” means, initially, the President of the Company and thereafter will mean such
director or other senior officer or employee of the Company as may be designated as Administrator by the Board from time to time. 

  

	 	(b)	 “Amended Articles” means the articles of the Company, as amended from time to time.

  

	 	(c)	 “Award Date” means the date on which the Board awards a particular Option or such other
effective award date determined by the Board. 

  

	 	(d)	 “Board” means the board of directors of the Company, or any committee thereof to which the
board of directors of the Company has delegated the power to administer and grant Options under the Plan. 

  

	 	(e)	 “Cause” means: 

 

	 	(i)	 Cause as such term is defined in the written employment agreement between the Company and the Option Holder; or

  

	 	(ii)	 in the event there is no written employment agreement between the Company and the Option Holder or Cause is not
defined therein, the usual meaning of just cause under the common law or the laws of the jurisdiction in which the Option Holder is employed. 

  

	 	(f)	 “Chairperson” means the chairperson of the Board. 

 

	 	(g)	 “Code” has the meaning given to that term under section 3.11. 

 

	 	(h)	 “Common Share” or “Common Shares” means, as the case may be, one or more
Class A Common Shares Without Par Value in the capital of the Company. 

  

	 	(i)	 “Consultant” means any individual, such as a service provider pursuant to a consulting or
services agreement, as may, from time to time, be permitted or not precluded by the rules and policies of the applicable Regulatory Authorities to be granted Options. 

 

	 	(j)	 “Company” means GenomeDx Biosciences Inc., a company incorporated under the laws of British
Columbia. 

  

	 	(k)	 “Compensation Committee” means the compensation committee of the Board, if and as constituted
from time to time. 

  

	 	(l)	 “Convertible Shares” has the meaning given to that term under section 3.4(f).

  
 1 

	 	(m)	 “Deemed Liquidation Event” has the meaning given to that term in the Amended Articles.

  

	 	(n)	 “Director” means any individual holding the office of director of the Company.

  

	 	(o)	 “Employee” means any individual regularly employed on a full or part-time basis by the Company
or any of its subsidiaries as may, from time to time, be permitted or not precluded by the rules and policies of the applicable Regulatory Authorities to be granted Options. 

 

	 	(p)	 “Equity Securities” means: 

 

	 	(i)	 Shares or any other security of the Company that carries the residual right to participate in the earnings of
the Company and, on liquidation, dissolution or winding-up, in the assets of the Company, whether or not the security carries voting rights; 

 

	 	(ii)	 any warrants, options or rights entitling the holders thereof to purchase or acquire any such securities; or

  

	 	(iii)	 any securities issued by the Company which are convertible or exchangeable into such securities.

  

	 	(q)	 “Exercise Notice” means the notice respecting the exercise of an Option, in the form set out
as Schedule B hereto, duly executed by the Option Holder. 

  

	 	(r)	 “Exercise Period” means the period during which a particular Option may be exercised and is
the period from and including the Award Date through to and including the Expiry Date. 

  

	 	(s)	 “Exercise Price” means the price at which an Option may be exercised as determined in
accordance with section 3.5. 

  

	 	(t)	 “Expiry Date” means the date determined in accordance with section 3.4 and after which a
particular Option cannot be exercised. 

  

	 	(u)	 “Fixed Expiry Date” has the meaning given to that term under section 3.4.

  

	 	(v)	 “IPO” means the offering and sale to the public of securities of the Company in connection
with which the securities of the Company are listed or quoted on an organized trading facility. 

  

	 	(w)	 “ISO” has the meaning given to that term under section 3.11. 

 

	 	(x)	 “Market Value” means the market value of the Common Shares as determined in accordance with
section 3.5. 

  

	 	(y)	 “Option” means an option to acquire Common Shares, awarded to a Director, Employee or
Consultant under the Plan. 

  

	 	(z)	 “Option Certificate” means the certificate, in the form set out as Schedule A hereto,
evidencing an Option. 

  
 2 

	 	(aa)	 “Option Holder” means a Director, Employee or Consultant, or former Director, Employee or
Consultant, who holds an unexercised and unexpired Option or, where applicable, the Personal Representative of such person. 

  

	 	(bb)	 “Person” means any individual, partnership, joint venture, syndicate, sole proprietorship,
company or corporation with or without share capital, trust, trustee, executor, administrator, or other legal personal representatives, regulatory body or agency, government or governmental agency, authority or entity howsoever designated or
constituted. 

  

	 	(cc)	 “Personal Representative” means: 

 

	 	(i)	 in the case of a deceased Option Holder, the executor or administrator of the deceased duly appointed by a
court or public authority having jurisdiction to do so; and 

  

	 	(ii)	 in the case of an Option Holder who for any reason is unable to manage his or her affairs, the person entitled
by law to act on behalf of such Option Holder. 

  

	 	(dd)	 “Plan” means this stock option plan. 

 

	 	(ee)	 “Purchaser” has the meaning given to that term under section 3.4(f).

  

	 	(ff)	 “Regulatory Authorities” means all stock exchanges, inter-dealer quotation networks and other
organized trading facilities on which the Shares are listed and all securities commissions or similar securities regulatory bodies having jurisdiction over the Company. 

 

	 	(gg)	 “Selling Shareholders” has the meaning given to that term under section 3.4(f).

  

	 	(hh)	 “Share” or “Shares” means, as the case may be, one or more Common Shares or
shares of any other class in the share capital of the Company from time to time. 

  

	 	(ii)	 “Substantial Sale” has the meaning given to that term under section 3.4(f).

  

	 	(jj)	 “Termination Date” means: 

 

	 	(i)	 in the case of the resignation of the Option Holder’s employment or the termination of the Option
Holder’s consulting or service contract by the Option Holder, the date that the Option Holder provides notice of such resignation or termination to the Company; or 

 

	 	(ii)	 in the case of the termination of the Option Holder’s employment or consulting or service contract by the
Company for any reason other than death or disability, the date that the Company delivers written notice of termination of the Option Holder’s employment or consulting or service contract to the Option Holder; or 

 

	 	(iii)	 in the case of the expiry of a fixed-term employment or consulting or service contract that is not renewed or
extended, the last day of the term. 

  

	 	(kk)	 “Transfer” includes any sale, exchange, assignment, gift, bequest, disposition, mortgage,
charge, pledge, encumbrance, grant of a security interest or other arrangement by which possession, legal title or beneficial ownership passes from one Person to another, or to the 

  
 3 

	 	
same Person in a different capacity, whether or not voluntarily and whether or not for value, and any agreement to effect any of the foregoing, including any sale or exchange pursuant to a plan
of arrangement, merger, consolidation, acquisition or similar transaction; and the words “Transferred”, “Transferring” and similar words have corresponding meanings. 

 

	 	(ll)	 “U.S. Participant” has the meaning given to that term under section 3.11.

  

	1.2	 Choice of Law 

The Plan is established under, and the provisions of the Plan will be subject to and interpreted and construed in accordance with, the laws of the Province of
British Columbia. 
  

	1.3	 Headings 

The headings used herein are for convenience only and are not to affect the interpretation of the Plan. 

ARTICLE 2 
 PURPOSE
AND PARTICIPATION 
  

	2.1	 Purpose 

The purpose of the Plan is to provide the Company with a share-related mechanism to attract, retain and motivate qualified Directors, Employees and
Consultants, to reward such of those Directors, Employees and Consultants as may be awarded Options under the Plan by the Board from time to time for their contributions toward the long term goals of the Company and to enable and encourage such
Directors, Employees and Consultants to acquire Common Shares as long term investments. 
  

	2.2	 Participation 

The Compensation Committee will, from time to time, recommend to the Board those Directors, Employees and Consultants, if any, to whom Options should be
awarded. The Board will, from time to time and in its sole discretion, taking into account any recommendations of the Compensation Committee, determine those Directors, Employees and Consultants, if any, to whom Options are to be awarded. The Board
may, in its sole discretion, grant the majority of the Options to insiders of the Company. 
  

	2.3	 Notification of Award 

Following the approval by the Board of the awarding of an Option, the Administrator will notify the Option Holder in writing of the award and will enclose
with such notice the Option Certificate representing the Option so awarded. 
  

	2.4	 Copy of Plan 

Each Option Holder, concurrently with the notice of the award of the Option, will be provided with a copy of the Plan. A copy of any amendment to the Plan
will be promptly provided by the Administrator to each Option Holder. 
  

	2.5	 Limitation 

The Plan does not give any Option Holder that is a Director the right to serve or continue to serve as a Director of the Company nor does it give any Option
Holder that is an Employee the right to be or to continue 

  
 4 

 
to be employed with the Company, nor does it give any Option Holder that is a Consultant the right to have a consulting relationship with the Company or provide services to the Company. 

ARTICLE 3 
 TERMS
AND CONDITIONS OF OPTIONS 
  

	3.1	 Board to Issue Common Shares 

The Common Shares to be issued to Option Holders upon the exercise of Options will be authorized and unissued Common Shares the issuance of which will have
been authorized by the Board. 
  

	3.2	 Number of Common Shares 

Subject to adjustment as provided for in section 3.9 of the Plan, the number of Common Shares that will be available for Directors, Employees and
Consultants to acquire pursuant to Options granted under the Plan will not exceed 24,121,603 Common Shares (including, for greater certainty, the Options outstanding as of the date hereof which shall be subject to and governed by the terms of this
Plan and the certificates governing each applicable grant of Options) and the maximum number of Common Shares that will be available for Directors, Employees and Consultants to acquire pursuant to ISOs (as defined in section 3.11 of this Plan) will
be 24,121,603 Common Shares. If any Option expires or otherwise terminates for any reason without having been exercised in full, the number of Common Shares in respect of which the Option was not exercised will again be available for the purposes of
the Plan. 
  

	3.3	 Term of Option 

An Option Holder may exercise an Option in whole or in part at any time or from time to time during the Exercise Period. Any Option or part thereof not
exercised within the Exercise Period will terminate and become null, void and of no effect as of 5:00 p.m. local time in Vancouver, British Columbia on the Expiry Date. 
  

	3.4	 Termination 

The Expiry Date of an Option will be the earlier of the date that is the tenth anniversary of the Award Date of such Option, or such other date so fixed by
the Board at the time the particular Option is awarded provided that such date will be no later than the tenth anniversary of the Award Date of such Option (the “Fixed Expiry Date”), or the date established, if applicable, in
subsections (a) to (f) below: 
  

	 	(a)	 Death 

In the event that the Option Holder should die while he or she is a Director (if he or she holds his or her Option as a Director) or Employee
(if he or she holds his or her Option as an Employee) or Consultant (if he or she holds his or her Option as a Consultant), the Expiry Date for any vested portion or portions of the Option will be the date that is twelve months after the date of the
Option Holder’s death. The Expiry Date for any unvested portion of the Option will be the date of the Option Holder’s death. 
  

	 	(b)	 Disability 

In the event that the Option Holder becomes permanently disabled while he or she is a Director (if he or she holds his or her Option as a
Director) or Employee (if he or she holds his or her Option as an Employee) or Consultant (if he or she holds his or her Option as a 

  
 5 

 Consultant) and ceases to be a Director, Employee or Consultant as a result of the permanent
disability, the Expiry Date for any vested portion or portions of the Option will be the date that is six months after the date that the Option Holder ceases to be a Director, Employee or Consultant, as the case may be. The Expiry Date for any
unvested portion of the Option will be the date that the Option Holder ceases to be a Director, Employee or Consultant, as the case may be. 
  

	 	(c)	 Ceasing to Hold Office 

In the event that the Option Holder holds his or her Option as a Director of the Company and such Option Holder ceases to be a Director of the
Company other than by reason of death or permanent disability, the Expiry Date for any vested portion or portions of the Option will be, unless otherwise provided for in the Option Certificate: 

 

	 	(i)	 the 90th day following the date that the Option Holder
ceases to be a Director of the Company 

 unless the Option Holder ceases to be a Director of the Company as a result of:

  

	 	(ii)	 ceasing to meet the qualifications required under applicable laws; 

 

	 	(iii)	 being removed from office in accordance with applicable laws; or 

 

	 	(iv)	 an order made by any Regulatory Authority having jurisdiction to so order, 

in which case the Expiry Date will be the date that the Option Holder ceases to be a Director of the Company. The Expiry Date for any unvested
portion of the Option will be the date that the Option Holder ceases to be a Director of the Company. 
  

	 	(d)	 Ceasing to be an Employee or Consultant 

In the event that the Option Holder holds his or her Option as an Employee or Consultant of the Company and such Option Holder ceases to be an
Employee or Consultant of the Company other than by reason of death or permanent disability, the Expiry Date of any vested portion or portions of the Option will be the 90th day following the
Termination Date unless the Option Holder ceases to be an Employee or Consultant of the Company as a result of: 
  

	 	(i)	 termination of employment for Cause (if he or she holds his or her Option as an Employee); or

  

	 	(ii)	 termination for failure to fulfil services pursuant to a consulting or services agreement (if he or she holds
his or her Option as a Consultant); or 

  

	 	(iii)	 an order made by any Regulatory Authority having jurisdiction to so order, 

in which case the Expiry Date will be the Termination Date. The Expiry Date for any unvested portion of the Option will be the Termination
Date. 

  
 6 

	 	(e)	 Initial Public Offering 

Prior to completion of an IPO, the Board or the Regulatory Authorities or the underwriter may require that there be no outstanding Options and
the Company may deliver a notice to the Option Holder to this effect, in which case the unvested portion of the Option held by the Option Holder, if any, will immediately vest and the Expiry Date of the Option will be the 30th day following the date of the notice. In the event that the Company does not complete the IPO, the Company will, to the extent reasonably practicable, grant to the Option Holder an Option equivalent
(including the original vesting terms, if any) to the Option cancelled or exercised, provided that in the case of an Option that was exercised, the Option Holder surrenders for cancellation the Common Shares acquired upon the exercise of the Option.

  

	 	(f)	 Substantial Sale 

For the purposes of this section 3.4(f), any capitalized terms used herein and not otherwise defined in this Agreement shall have the meaning
ascribed thereto in Article 27 of the amended articles of the Company (the “Amended Articles”). 
  

	 	(i)	 Drag-Along. 

If Shareholders holding Shares representing at least 61% of the outstanding Shares (the “Selling Shareholders”) irrevocably agree to
Transfer (as defined in the Amended Articles) to one or more Persons (as defined in the Amended Articles) acting as principal and who is or are independent of the Selling Shareholders (a “Purchaser”) all or some portion of the Shares held
or beneficially owned by the Selling Shareholders (collectively, the “Offered Securities”) pursuant to a bona fide offer, agreement or Deemed Liquidation Event (collectively, a “Purchase Offer”) from or with the Purchaser, the
Selling Shareholders shall have the right (the “Drag-Along Right”), but not the obligation, to require each of the other holders or beneficial owners of Shares (the “Other Securityholders”) to sell the same proportion of Shares
of the Company beneficially owned by such Other Securityholders as is being sold by the Selling Shareholders (collectively, the “Drag-Along Securities”) to the Purchaser for an amount and on the terms and conditions set out in this section
3.4(f) and in accordance with Article 27 of the Amended Articles, provided for greater certainty, notwithstanding this section 3.4(f)(i), in no event shall the Other Securityholders be required to sell any fractional Shares and in the event that the
proportion of Shares required to be sold by any Other Securityholder pursuant to this section 3.4(f)(i) includes a fractional share, such number of Shares required to be sold by such Other Securityholder shall be rounded down to the nearest whole
number. If the Purchaser offers to purchase any outstanding Options or requires that there be no Options outstanding following completion of the transactions contemplated in the Purchase Offer, this section 3.4(f)(i) shall be applicable to then
outstanding Options and such Options shall be “Drag-Along Securities” for purposes of this section 3.4(f)(i) and Selling Shareholder may require the Company to deliver a notice to the Option Holder requiring the sale of such Options
pursuant hereto, or, if applicable, provide that the unvested portion of the Option held by the Option Holder, if any, will immediately vest and the Expiry Date of the Option will be the 30th day following the date of the notice. 

  
 7 

	 	(ii)	 Other Restrictions. 

No Option Holder that may be required to sell Shares pursuant to this section 3.4(f) shall deposit, or permit any of their Affiliates to
deposit, except as provided in this section 3.4(f) and in accordance with Article 27 of the Amended Articles, any Shares beneficially owned by such holder or Affiliate in any voting trust or subject any Shares to any agreement or arrangement with
respect to the voting of such securities (other than proxies that may be granted from time to time in respect of specific meetings), unless specifically requested to do so by the Purchaser in connection with a sale pursuant to this section 3.4(f).

  

	 	(iii)	 Acknowledgement of Article 27. 

Each Optionholder confirms and acknowledges that any Purchase Offer made and Drag-Along Right exercised under this section 3.4(f) is subject
to and shall be made in accordance with the terms and conditions of Article 27 of the Amended Articles, to be read with such amendments as are necessary to reflect that Options are “Drag-Along Securities”. 

If the Purchaser offers to buy the Options of an Option Holder and the Option Holder does not sell the Option Holder’s Options to the
Purchaser as contemplated above, then that Option Holder’s Options will expire, terminate and be cancelled on completion of the Substantial Sale. 

Notwithstanding section 3.4(f) above, the Board may, in a manner no less favourable from a financial point of view to an Option Holder than the treatment
provided in section 3.4(f) above, determine the manner in which all unexercised Options granted under this Plan will be treated in the event of a Substantial Sale. 

Notwithstanding anything else contained in the Plan and subject to any necessary approval from the Company’s shareholders and the Regulatory Authorities,
the Board may in its discretion (a) extend the Expiry Date of any Option, provided that in no case will an Option be exercisable later than the tenth anniversary of the Award Date of the Option; or (b) accelerate the expiry or vesting
terms applicable to an Option. 
  

	3.5	 Exercise Price 

The price at which an Option Holder may purchase a Common Share upon the exercise of an Option will be as set forth in the Option Certificate issued in
respect of such Option and in any event will not be less than the Market Value of the Common Shares as of the Award Date. The Market Value of the Common Shares for a particular Award Date will be determined as follows: 

 

	 	(a)	 for each organized trading facility on which the Common Shares are listed, Market Value will be determined by a
resolution of the Board and must be either: 

  

	 	(i)	 the closing trading price of the Common Shares on the last trading day immediately preceding the Award Date; or

  

	 	(ii)	 a value that is within the parameters set by the guidelines or policies of such organized trading facility;

  

	 	(b)	 if the Common Shares trade on an organized trading facility outside of Canada, then the Market Value determined
for that organized trading facility will be converted into Canadian 

  
 8 

	 	dollars at a conversion rate determined by the Administrator having regard for the published conversion rates as of the Award Date; 

  

	 	(c)	 if the Common Shares are listed on more than one organized trading facility, then Market Value will be the
greatest of the Market Values determined for each organized trading facility on which those Common Shares are listed as determined for each organized trading facility in accordance with subsections (a) and (b) above; 

 

	 	(d)	 if the Common Shares are listed on one or more organized trading facility but have not traded during the ten
trading day period immediately preceding the Award Date, then the Market Value will be, subject to the necessary approvals of the applicable Regulatory Authorities, such value as is determined by the Board; and 

 

	 	(e)	 if the Common Shares are not listed on any organized trading facility, then the Market Value will be, subject
to the necessary approvals of the applicable Regulatory Authorities, such value as is determined by the Board. 

 Notwithstanding anything
else contained herein, in no case will the Market Value be less than the minimum prescribed by each of the organized trading facilities as would apply to the Award Date in question. 

 

	3.6	 Additional Terms 

Subject to all applicable securities laws and regulations and the rules and policies of all applicable Regulatory Authorities, the Board may attach other
terms and conditions to the grant of a particular Option, such terms and conditions to be referred to in a schedule attached to the Option Certificate. These terms and conditions may include, but are not necessarily limited to, the following: 

 

	 	(a)	 providing that an Option expires on a date other than as provided for herein, provided that in no case will an
Option be exercisable later than the tenth anniversary of the Award Date of the Option; 

  

	 	(b)	 providing that a portion or portions of an Option vest after certain periods of time or upon the occurrence of
certain events, or expire after certain periods of time or upon the occurrence of certain events other than as provided for herein; and 

  

	 	(c)	 providing that an Option be exercisable immediately, in full, notwithstanding that it has vesting provisions,
upon the occurrence of certain events, such as a friendly or hostile takeover bid for the Company. 

  

	3.7	 Going Public Agreements 

If the Company proceeds to list its Shares on a public stock exchange or commences a public offering, each Option Holder will promptly enter into all such
escrow, pooling or other agreements as are required by the securities regulatory authorities, the exchange, the agents or the underwriters in connection with such listing or public offering. 

 

	3.8	 Assignment of Options 

Options may not be assigned or transferred, provided however that the Personal Representative of an Option Holder may, to the extent permitted by
section 4.1, exercise the Option within the Exercise Period. 

  
 9 

	3.9	 Adjustments 

If prior to the complete exercise of an Option the Common Shares are consolidated, subdivided, converted, exchanged or reclassified or in any way substituted
for (collectively, the “Event”), an Option, to the extent that it has not been exercised, will be adjusted by the Board in accordance with such Event in the manner the Board deems appropriate. No fractional Common Shares will be
issued upon the exercise of an Option and accordingly, if as a result of the Event, an Option Holder would become entitled to a fractional Common Share, such Option Holder will have the right to purchase only the next lowest whole number of Common
Shares and no payment or other adjustment will be made with respect to the fractional interest so disregarded. 
  

	3.10	 Option Grant and Vesting Terms 

Unless otherwise determined by the Board in accordance with the terms and conditions of this Plan, Options will be granted by the Board. The Board may, in its
sole discretion attach a term or condition to a particular grant of Options providing that such Options will vest over a certain period of time or upon the occurrence of certain events. Unless otherwise determined by the Board, in its sole
discretion, all grants of Options will vest over a four year period, with the first twenty-five percent (25%) of the Common Shares underlying each Option to vest following twelve months of continued employment or service, and the remaining Common
Shares vesting over the following thirty-six month period in equal instalments on a monthly basis. 
 For clarity,
the Board may deviate from the terms of this section 3.10 with respect to the grant of Options provided that such grant is made in accordance with the other terms of this Plan. 

 

	3.11	 U.S. Participants 

Any Option granted under the Plan to an Option Holder who is a citizen or resident of the United States (including its territories, possessions and all areas
subject to the jurisdiction) (a “U.S. Participant”) may, at the sole discretion of the Company, be an incentive stock option (an “ISO”) within the meaning of Section 422 of the Internal Revenue Code of 1986, as
amended, of the United States (the “Code”), but only if so designated by the Company in the Option Certificate evidencing such Option. No provision of this Plan, as it may be applied to a U.S. Participant with respect to Options
which are designated as ISOs, shall be construed so as to be inconsistent with any provision of Section 422 of the Code or the Treasury Regulations thereunder. Grants of Options to U.S. Participants which are not designated as or otherwise do
not qualify as ISOs will be treated as nonstatutory stock options for U.S. federal tax purposes. Notwithstanding anything in this Plan contained to the contrary, the following provisions shall apply to ISOs granted to each U.S. Participant: 

 

	 	(a)	 ISOs shall only be granted to individual U.S. Participants who are, at the time of grant, employees of the
Company within the meaning of the Code. Any director of the Company who is a U.S. Participant shall be ineligible to vote upon the granting of such Option; 

  

	 	(b)	 the aggregate fair market value (determined as of the time an ISO is granted) of the Common Shares subject to
ISOs exercisable for the first time by a U.S. Participant during any calendar year under this Plan and all other stock option plans, within the meaning of Section 422 of the Code, of the Company shall not exceed One Hundred Thousand Dollars in
U.S. funds (U.S.$100,000); 

  

	 	(c)	 the Exercise Price for Common Shares under each ISO granted to a U.S. Participant pursuant to this Plan shall
be not less than fair market value of such Common Shares at the time the Option is granted, as determined in good faith by the Board at such time (unless such ISO is granted pursuant to an assumption or substitution for another option in a manner
satisfying the provisions of Section 424(a) of the Code); 

  
 10 

	 	(d)	 if any U.S. Participant to whom an ISO is to be granted under the Plan at the time of the grant of such ISO is
the owner of shares possessing more than ten percent (10%) of the total combined voting power of all classes of shares of the Corporation, then the following special provisions shall be applicable to the ISO granted to such individual:

  

	 	(i)	 the Exercise Price (per share) subject to such ISO shall not be less than one hundred ten percent (110%) of the
fair market value of one Common Share at the time of grant; and 

  

	 	(ii)	 for the purposes of this section 3.11 only, the Exercise Period shall not exceed five (5) years from the
date of grant; 

  

	 	(e)	 no ISO may be granted hereunder to a U.S. Participant following the expiration of ten (10) years after the
date on which this Plan is adopted by the Company or the date on which the Plan is approved by the shareholders of the Company, whichever is earlier; and 

  

	 	(f)	 no ISO granted to a U.S. Participant under the Plan shall become exercisable unless and until the Plan shall
have been approved by the shareholders of the Company. 

 ARTICLE 4 

EXERCISE OF OPTION 
  

	4.1	 Exercise of Option 

An Option may be exercised only by the Option Holder or the Personal Representative of the Option Holder. An Option Holder or the Personal Representative of
the Option Holder may exercise the vested portion or portions of an Option in whole or in part at any time or from time to time during the Exercise Period up to 5:00 p.m. local time in Vancouver, British Columbia on the Expiry Date by delivering to
the Administrator an Exercise Notice, the applicable Option Certificate and a certified cheque or bank draft payable to “GenomeDx Biosciences Inc.” in an amount equal to the aggregate Exercise Price of the Common Shares to be
purchased pursuant to the exercise of the Option. 
  

	4.2	 Shareholder’s Agreement 

It is a condition of the Plan that an Option Holder who wishes to exercise an Option in whole or in part prior to the completion of an IPO must, if required
by the Board, be a party to a shareholder’s agreement with the Company substantially in the form set out as Schedule C hereto. The shareholder’s agreement establishes certain rights and obligations with respect to the holding and sale
of all Common Shares purchased from time to time by the Option Holder upon the exercise of Options. 
  

	4.3	 Execution of Shareholder’s Agreement 

As soon as practicable following the receipt of the Exercise Notice, the Administrator will establish whether the Option Holder is a party to a
shareholder’s agreement with the Company. If the Option Holder is not a party to a shareholder’s agreement, and if so required by the Board, the Administrator will cause to be delivered to the Option Holder a shareholder’s agreement
substantially in the form set out as Schedule C hereto for execution by the Option Holder and return to the Administrator. 

  
 11 

	4.4	 Issue of Share Certificates 

As soon as practicable following the receipt of the Exercise Notice (or following receipt of the executed shareholder’s agreement, if required), the
Administrator will, in his sole discretion, either cause to be delivered to the Option Holder a certificate for the Common Shares purchased by the Option Holder or cause to be delivered to the Option Holder a copy of such certificate and the
original of such certificate will be placed in the minute book of the Company. If the number of Common Shares in respect of which the Option was exercised is less than the number of Common Shares subject to the Option Certificate surrendered, the
Administrator will forward a new Option Certificate to the Option Holder concurrently with delivery of the share certificate for the balance of the Common Shares available under the Option. 

 

	4.5	 Condition of Issue 

The Options and the issue of Common Shares by the Company pursuant to the exercise of Options are subject to the terms and conditions of the Plan and
compliance with the rules and policies of all applicable Regulatory Authorities with respect to the granting of such Options and the issuance and distribution of such Common Shares, and to all applicable securities laws and regulations. The Option
Holder agrees to comply with all such laws, regulations, rules and policies and agrees to furnish to the Company any information, reports or undertakings required to comply with, and to fully cooperate with, the Company in complying with such laws,
regulations, rules and policies. 
 ARTICLE 5 

ADMINISTRATION 
  

	5.1	 Administration 

The Plan will be administered by the Administrator on the instructions of the Board. The Compensation Committee may, from time to time, recommend to the Board
how the Plan should be administered. The Board may make, amend and repeal at any time and from time to time such policies not inconsistent with the Plan as it may deem necessary or advisable for the proper administration and operation of the Plan
and such policies will form part of the Plan. The Board may delegate to the Administrator or any director, officer or employee of the Company such administrative duties and powers as it may see fit. 

 

	5.2	 Interpretation 

The interpretation by the Board of any of the provisions of the Plan and any determination by it pursuant thereto will be final and conclusive and will not be
subject to any dispute by any Option Holder. No member of the Board or any person acting pursuant to authority delegated by it hereunder will be liable for any action or determination in connection with the Plan made or taken in good faith and each
member of the Board and each such person will be entitled to indemnification with respect to any such action or determination in the manner provided for by the Company. 

ARTICLE 6 

AMENDMENT, TERMINATION AND NOTICE 
  

	6.1	 Prospective Amendment 

The Board may, from time to time and in accordance with any third party obligations of the Company, amend the Plan and the terms and conditions of any Option
thereafter to be granted and, without limiting the generality of the foregoing, may make such amendment for the purpose of meeting any changes in any relevant law, rule or regulation applicable to the Plan, any Option or the Common Shares, or for
any other 

  
 12 

 purpose which may be permitted by all relevant laws, regulations, rules and policies provided always that
any such amendment (with the exception of an amendment pursuant to section 3.4(f)) will not alter the terms or conditions of any Option or impair any right of any Option Holder pursuant to any Option awarded prior to such amendment. 

 

	6.2	 Retrospective Amendment 

The Board may from time to time retrospectively amend the Plan and, with the consent of the affected Option Holders, retrospectively amend the terms and
conditions of any Options which have been previously granted. 
  

	6.3	 Approvals 

The Plan and any amendments hereto are subject to all necessary approvals of the applicable Regulatory Authorities. 

 

	6.4	 Termination 

The Board may terminate the Plan at any time provided that such termination will not alter the terms or conditions of any Option or impair any right of any
Option Holder pursuant to any Option awarded prior to the date of such termination which will continue to be governed by the provisions of the Plan. 
  

	6.5	 Agreement 

The Company and every Option awarded hereunder will be bound by and subject to the terms and conditions of the Plan. By accepting an Option granted hereunder,
the Option Holder has expressly agreed with the Company to be bound by the terms and conditions of the Plan. 
  

	6.6	 Notice 

Any notice or other communication contemplated under the Plan to be given by the Company to an Option Holder will be given by the Company delivering or faxing
the notice to the Option Holder at the last address for the Option Holder in the Company’s records. Any such notice will be deemed to have been given on the date on which it was delivered, or in the case of fax, the next business day after
transmission. An Option Holder may, at any time, advise the Company of a change in the Option Holder’s address or fax number. 

  
 13 

 AMENDMENT NO. 2 TO 

GENOMEDX BIOSCIENCES INC. 

2011 AMENDED STOCK OPTION PLAN 

WHEREAS, DECIPHER BIOSCIENCES, INC., a Delaware
corporation (the “Company”), has adopted the Genomedx Biosciences Inc. 2011 Amended Stock Option Plan, effective December 2, 2011 and as amended September 18, 2013 (the “Plan”); and 

WHEREAS, pursuant to Article 6 of the Plan, the Board of Directors of the Company desires to amend
Section 5.1 of the Plan to provide that the Board may reprice options. 
 NOW
THEREFORE, the Plan is hereby amended as follows, effective as of June 10, 2019: 
 1. Section 5.1 of
the Plan is hereby amended by replacing such section in its entirety with the following: 
 “The Plan will be administered by the
Administrator on the instructions of the Board. The Compensation Committee may, from time to time, recommend to the Board how the Plan should be administered. The Board may make, amend and repeal at any time and from time to time such policies not
inconsistent with the Plan as it may deem necessary or advisable for the proper administration and operation of the Plan and such policies will form part of the Plan. The Board may delegate to the Administrator or any director, officer or employee
of the Company such administrative duties and powers as it may see fit. 
 The Board may effect, with the consent of any adversely affected
Option Holder, (A) the reduction of the exercise, purchase or strike price of any outstanding Option; (B) the cancellation of any outstanding Option and the grant in substitution therefor of a new (1) Option or (2) cash and/or
consideration determined by the Board, in its sole discretion, with any such substituted award (x) covering the same or a different number of shares of Common Shares as the cancelled Option and (y) granted under the Plan or another equity
or compensatory plan of the Company; or (C) any other action that is treated as a repricing under generally accepted accounting principles.” 

2. All other terms and conditions of the Plan shall remain in full force and effect. 

3. Capitalized terms used herein and not otherwise defined herein shall have the meanings set forth in the Plan. 

  
 14 

 IN WITNESS WHEREOF, the
Company has caused this instrument to be executed in its name and on its behalf, effective as stated herein. 
  

			
	DECIPHER BIOSCIENCES, INC.
		
	By:	 	/s/ Tina S. Nova, Ph.D. 

 
			
	Name:	 	Tina S. Nova, Ph.D.
	Title:	 	President and Chief Executive Officer

  
 15 

 SCHEDULE A 

GENOMEDX BIOSCIENCES INC. 

STOCK OPTION PLAN 
 OPTION CERTIFICATE

 This Certificate is issued pursuant to the provisions of the GenomeDx Biosciences Inc. (the “Company”) stock option plan (the
“Plan”) and evidences that ● is the holder (the “Option Holder”) of an option (the “Option”) to purchase up to ● Common Shares Without Par Value (the “Common Shares”) in
the capital stock of the Company. The Exercise Price of the Option is Cdn. $ ● per Common Share. 
 Subject to the provisions of the Plan: 

 

	 	(a)	 the Award Date of the Option is ●, ● ; and 

 

	 	(b)	 the Fixed Expiry Date of the Option is ●, ● . 

The vested portion or portions of the Option may be exercised at any time and from time to time from and including the Award Date through to 5:00 p.m. local
time in Vancouver, British Columbia on the Expiry Date by delivering to the Administrator of the Plan an Exercise Notice, in the form provided in the Plan, together with this Certificate and a certified cheque or bank draft payable to “GenomeDx
Bioscience Inc.” in an amount equal to the aggregate of the Exercise Price of the Common Shares in respect of which the Option is being exercised. 

Upon receiving the Exercise Notice, the Administrator may deliver a shareholder’s agreement substantially in the form set out as Schedule C to the
Plan to the Option Holder. The Option and the issue of Common Shares by the Company pursuant to the exercise of the Option are subject to the Option Holder signing and returning to the Administrator a copy of the shareholder’s agreement, if so
required by the Administrator. 
 This Certificate and the Option evidenced hereby are not assignable, transferable or negotiable and are subject to the
detailed terms and conditions contained in the Plan, the terms and conditions of which the Option Holder hereby expressly agrees with the Company to be bound by. This Certificate is issued for convenience only and in the case of any dispute with
regard to any matter in respect hereof, the provisions of the Plan and the records of the Company will prevail. 
 The Option is also subject to the terms
and conditions contained in the schedules, if any, attached hereto. All terms not otherwise defined in this Certificate will have the meanings given to them under the Plan. 

Dated this ● day of ●, ● . 
  

			
	GENOMEDX BIOSCIENCES INC.
		
	Per:	 	 
	 	 	Administrator, Stock Option Plan
GenomeDx Biosciences Inc.

  
 A-1 

 OPTION CERTIFICATE—SCHEDULE 

The additional terms and conditions attached to the Option represented by this Certificate are as follows: 

1 ● ; and 
 2 ● . 

 

			
	GENOMEDX BIOSCIENCES INC.
		
	Per:	 	 
	 	 	Administrator, Stock Option Plan
GenomeDx Biosciences Inc.

  
 A-2 

 SCHEDULE B 

GENOMEDX BIOSCIENCES INC. 

STOCK OPTION PLAN 
 NOTICE
OF EXERCISE OF OPTION 
 TO: The Administrator, Stock Option Plan 

GenomeDx Biosciences Inc. 
 c/o
Joseph Garcia 
 2600 – 595 Burrard Street, Three Bentall Centre 

Vancouver, British Columbia, V7X 1L3 
 The
undersigned hereby irrevocably gives notice, pursuant to the GenomeDx Biosciences Inc. stock option plan (the “Plan”), of the exercise of the Option to acquire and hereby subscribes for (cross out inapplicable item): 

 

	 	(a)	 all of the Common Shares; or 

 

	 	(b)	 ___________________ of the Common Shares, 

which are the subject of the Option Certificate attached hereto. 

The undersigned tenders herewith a certified cheque or bank draft (circle one) payable to “GenomeDx Biosciences Inc.” in an amount equal to
the aggregate Exercise Price of the aforesaid Common Shares and directs the Company to issue the certificate evidencing said Common Shares in the name of the undersigned to be mailed to the undersigned at the following address: 

 

			
		 	 
		
		 	 
		
		 	 

 The undersigned acknowledges that upon receiving the Exercise Notice, the Administrator may deliver a shareholder’s
agreement substantially in the form set out as Schedule C to the Plan to the undersigned. The Option and the issue of Common Shares by the Company pursuant to the exercise of the Option are subject to the undersigned signing and returning to
the Administrator a copy of the shareholder’s agreement, if so required by the Administrator. 
 By executing this Notice of Exercise of Option the
undersigned hereby confirms that the undersigned has read the Plan and agrees to be bound by the provisions of the Plan, including without limitation section 4.2. All terms not otherwise defined in this Notice of Exercise of Option will have
the meanings given to them under the Option Certificate. 
 DATED the ________ day of ____________________, __________. 

 

	
	   

	Signature of Option Holder

  
 B-1 

 SCHEDULE C 

GENOMEDX BIOSCIENCES INC. 

STOCK OPTION PLAN 

SHAREHOLDER’S AGREEMENT 
 THIS
AGREEMENT is dated for reference the ● day of ●, 20●. 
 BETWEEN: 

GenomeDx Biosciences Inc., a company incorporated under the laws of British Columbia, with a registered office at ●; 

(the “Company”) 
 AND: 

●, of ●, British Columbia, ●; 

(the “Shareholder”) 
 WHEREAS:

  

	A.	 The Shareholder wishes to acquire Shares in the capital of the Company upon the exercise of stock options
granted under the Company’s stock option plan dated ● (the “Plan”), on the condition that this Agreement be entered into; and 

  

	B.	 The parties wish to establish certain rights and obligations in respect of the holding and sale of the Shares
and certain other matters; 

 NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of the premises, the mutual covenants and
agreements set forth in this Agreement and other good and valuable consideration (the receipt and sufficiency of which is hereby acknowledged by each of the parties), the parties hereby agree as follows: 

ARTICLE 1 

INTERPRETATION 
  

	1.1	 Definitions 

In this Agreement, unless otherwise provided: 
  

	 	(a)	 “Affiliate” means, with respect to the Shareholder, any company that is directly or indirectly
Controlled by the Shareholder. 

  

	 	(b)	 “Agreement” means this agreement, together with any amendments to or replacements of this
agreement. 

  

	 	(c)	 “Acquisition Notice” has the meaning given to that term under subsection 3.4(a).

  
 C-1 

	 	(d)	 “Acquisition Offer” means a bona fide offer to purchase all of the Equity Securities that is
received prior to the completion of an IPO. 

  

	 	(e)	 “Board” means the board of directors of the Company. 

 

	 	(f)	 “Business” means (i) the business of developing biomarker technologies to screen people
for diseases that when identified can be promptly treated, thereby deriving the benefit of earlier detection and greater treatment success and (ii) any other material business carried on from time to time by the Company. 

 

	 	(g)	 “Competitive Business” means any firm, company or business that competes in a material way
with the Business of the Company. 

  

	 	(h)	 “Constating Documents” means the Certificate of Incorporation, Notice of Articles, an
Articles, together with any amendments thereto or replacements thereof. 

  

	 	(i)	 “Control” or “Controls” means: 

 

	 	(i)	 the right to exercise a majority of the votes that may be cast at a general meeting of a company, including
votes that are exercisable only upon the occurrence of a contingency, where such contingency has occurred and is continuing; or 

  

	 	(ii)	 the right to elect or appoint, directly or indirectly, a majority of the directors of a company or other
persons who have the right to manage or supervise the management of the affairs and business of the company. 

  

	 	(j)	 “Company Notice” has the meaning given to that term under subsection 3.3(b).

  

	 	(k)	 “Equity Securities” means: 

 

	 	(i)	 common shares or any other security of the Company that carries the residual right to participate in the
earnings of the Company and, on liquidation, dissolution or winding-up, in the assets of the Company, whether or not the security carries voting rights; 

 

	 	(ii)	 any warrants, options or rights entitling the holders thereof to purchase or acquire any such common shares or
other securities; or 

  

	 	(iii)	 any securities issued by the Company which are convertible or exchangeable into such common shares or other
securities; 

  

	 	(l)	 “First Refusal Company Notice” has the meaning given to that term under subsection 3.3(b).

  

	 	(m)	 “First Refusal Offer” has the meaning given to that term under section 3.3.

  

	 	(n)	 “First Refusal Offer Notice” has the meaning given to that term under subsection 3.3(a).

  

	 	(o)	 “IPO” means the offering and sale to the public of any Equity Securities in connection with
which such Equity Securities are listed or quoted on an organized trading facility. 

  
 C-2 

	 	(p)	 “Offered Shares” has the meaning given to that term under section 3.3. 

 

	 	(q)	 “Offering Period” has the meaning given to that term under subsection 3.3(b).

  

	 	(r)	 “Offeror” has the meaning given to that term under section 3.4. 

 

	 	(s)	 “Person” means any individual, partnership, limited partnership, joint venture, syndicate,
sole proprietorship, company or corporation with or without share capital, unincorporated association, trust, trustee, executor, administrator or other legal personal representative, regulatory body or agency, government or governmental agency,
authority or entity however designated or constituted. 

  

	 	(t)	 “Purchase Price” has the meaning given to that term under subsection 3.4(c).

  

	 	(u)	 “Regulatory Authorities” means all stock exchanges, inter-dealer quotation networks and other
organized trading facilities on which any Equity Securities are listed and all securities commissions or similar securities regulatory bodies having jurisdiction over the Company. 

 

	 	(v)	 “Repurchase Notice” has the meaning given to that term under section 3.4.

  

	 	(w)	 “Repurchase Price” means the fair market value of the Shares being repurchased as determined
by the Board with advice from, but not limited to, the auditors or accountants of the Company in accordance with generally accepted accounting principles using such factors as the auditors or accountants of the Company consider reasonable for the
purposes of valuing the Shares, such determination to be final and binding upon the parties. 

  

	 	(x)	 “Shares” means any and all common shares in the capital of the Company that have been
purchased or may in the future be purchased by the Shareholder, including without limitation, common shares in the capital of the Company that have been purchased or may in the future be purchased upon the exercise of stock options granted under the
Plan. 

  

	 	(y)	 “Specified Securities” has the meaning given to that term under subsection 3.4(a).

  

	 	(z)	 “Transfer” includes any sale, exchange, assignment, gift, bequest, disposition, mortgage,
charge, pledge, encumbrance, grant of a security interest or other arrangement by which possession, legal title or beneficial ownership passes from one Person to another, or to the same Person in a different capacity, whether or not voluntarily and
whether or not for value, and any agreement to effect any of the foregoing and the words “Transferred”, “Transferring” and similar words have corresponding meanings. 

 

	1.2	 Words 

Words (including defined terms) using or importing the singular number include the plural and vice versa and words importing one gender only will include all
genders and words importing persons in this Agreement will include individuals, partnerships, corporations and any other entities, legal or otherwise. 
  

	1.3	 Headings 

The headings used in this Agreement are for ease of reference only and will not affect the meaning or the interpretation of this Agreement. 

  
 C-3 

 ARTICLE 2 

SCOPE, EFFECT AND PARTIES 
  

	2.1	 Shareholder to Act in Support of Terms 

The Shareholder will at all times promptly take all such steps as may be reasonably within his or her powers, so as to fully implement the terms of this
Agreement. 
  

	2.2	 Terms to Prevail over Constating Documents 

In the event of any conflict between the provisions of this Agreement and the Constating Documents or any agreement to which the Company or the Shareholder is
or becomes a party, the provisions of this Agreement will prevail and govern to the extent permitted by law, provided, that in the event that the Shareholder is a party to any of the Amended and Restated Investors’ Rights Agreement, the Amended
and Restated Voting Agreement or the Amended and Restated Right of First Refusal and Co-Sale Agreement, each dated September 18, 2013, by and among the Company and certain of its shareholders (as the same
maybe amended or restated from time to time, the “Transaction Agreements”), the provisions of each applicable Transaction Agreement will prevail and govern in precedence to this Agreement and any other agreement to which the Company
or the Shareholder is or becomes a party to the extent permitted by law. 
  

	2.3	 Ceasing to be a Party 

If the Shareholder no longer holds any Shares, then from that point forward the Shareholder will be deemed no longer to be a party to this Agreement. 

 

	2.4	 Termination of Agreement 

This Agreement and all of the benefits, rights and obligations hereunder will terminate in the event the Company is dissolved, liquidated or formally wound-up or upon an IPO. 
  

	2.5	 Amendment of Agreement 

This Agreement may only be amended by an instrument in writing duly executed by the Company and the Shareholder. 

ARTICLE 3 
 SHARE
TRANSFERS 
  

	3.1	 Transfers Restricted 

The Shareholder will not, directly or indirectly, Transfer any Shares (including but not restricted to any disposition by agreement, option, right or
privilege capable of becoming an agreement or option) except (i) as permitted under section 3.2; or (ii) in accordance with the procedure set out under section 3.3. 

 

	3.2	 Permitted Transfers 

Section 3.3 of this Agreement does not apply to the following Transfers of Shares, which, subject to compliance with applicable securities laws, are
permitted under this Agreement: 
  

	 	(a)	 the Shareholder may from time to time Transfer all or any part of his or her Shares to any Affiliate of the
Shareholder, provided that (i) the Shareholder Controls the Affiliate for so 

  
 C-4 

	 	
long as the Affiliate holds the Shares and will cause the Affiliate to observe all of the terms of this Agreement; (ii) the Affiliate agrees as a condition of the Transfer to be bound by and
have the benefit of this Agreement; and (ii) the Affiliate agrees as a condition of the Transfer to Transfer back such Shares to the Shareholder in the event that the Affiliate ceases to be an Affiliate of the Shareholder. Notwithstanding
section 2.3, any such Transfer will not release the Shareholder from his or her obligations hereunder; 

  

	 	(b)	 the Shareholder may from time to time Transfer all or any part of his or her Shares to: 

 

	 	(i)	 a trust for the benefit of the Shareholder or his or her immediate family; or 

 

	 	(ii)	 a registered retirement savings plan of the Shareholder or the spouse of the Shareholder,

 provided that if such transferee(s) (both legal and beneficial transferees in the case of a trust) is required to become
a party to this Agreement, such transferee(s) will designate the Shareholder to represent the transferee(s) and the Shareholder will remain a party to and be bound by this Agreement for and on behalf of such transferee(s) and the Shareholder.
Notwithstanding section 2.3, any such Transfer will not release the Shareholder from his or her obligations hereunder; 
  

	 	(c)	 upon the death of the Shareholder, the Shareholder’s Shares may be Transferred in accordance with a
probated will of the deceased or by operation of laws for the administration of estates upon intestacy, provided that each such transferee enters into an agreement under which the transferee becomes party to and bound by this Agreement;

  

	 	(d)	 a Transfer of Shares pursuant to section 3.4; and 

 

	 	(e)	 the Shareholder may Transfer Shares in accordance with the rights, privileges, restrictions and conditions
attached to Shares or a Transfer of Shares under a repurchase of Shares by the Company. 

  

	3.3	 Right of First Refusal 

If the Shareholder desires to Transfer any of his or her Shares, he or she may only do so if the Shareholder first offers (the “First Refusal
Offer”) the Company the prior right to purchase, receive or acquire such Shares (the “Offered Shares”) on the following basis: 
  

	 	(a)	 the First Refusal Offer will be made by written notice to the Company (the “First Refusal Offer
Notice”) and will specify (i) the number of Offered Shares; (ii) the price at which the Shareholder is prepared to sell the Offered Shares; (iii) any other terms and conditions applicable to the First Refusal Offer; and
(iv) whether or not the Shareholder has received a third party offer to purchase any of the Offered Shares (in which case the third party offer must be attached to the First Refusal Offer Notice); 

 

	 	(b)	 the Company will have the right to accept the First Refusal Offer and purchase all, but not less than all, of
the Offered Shares from the Shareholder. The Company will have 14 days (the “Offering Period”) after receipt of the First Refusal Offer Notice to deliver to the Shareholder written notice (the “First Refusal Company
Notice”) that the Company either accepts the First Refusal Offer in its entirety or not at all. Failure to deliver the First Refusal Company Notice will be deemed to be a rejection of the First Refusal Offer; 

  
 C-5 

	 	(c)	 if the Company does not accept the First Refusal Offer, then the Shareholder may Transfer all, but not less
than all, of the Offered Shares to a third party, provided that: 

  

	 	(i)	 such Transfer is effected at a price that is not less than the price and on terms and conditions no more
favourable (from a purchaser’s perspective) than those set forth in the First Refusal Offer Notice; 

  

	 	(ii)	 the Shareholder will not Transfer any of the Offered Shares to a third party who is engaged in a Competitive
Business unless the First Refusal Offer Notice originally delivered by the Shareholder attached a detailed written offer from the third party for the Offered Shares; and 

 

	 	(iii)	 such transfer is completed within a 90 day period following the end of the Offering Period (after which period
has expired the Shareholder must again comply with this section 3.3 before Transferring any of his or her Shares to any Person); 

  

	 	(d)	 the closing of the purchase of the Offered Shares by the Company will take place at the Company’s office
on the later of: (i) the closing date specified in the First Refusal Offer Notice; and (ii) 30 days following the delivery of the First Refusal Company Notice to the Shareholder; and 

 

	 	(e)	 the Shareholder will not Transfer the Offered Shares to a Person unless such Person is already party to a
shareholder’s agreement with the Company or becomes party to and bound by this Agreement. 

  

	3.4	 Drag-Along Right 

For the purposes of this section 3.4, any capitalized terms used herein and not otherwise defined in this Agreement shall have the meaning ascribed thereto in
Article 27 of the amended articles of the Company (the “Amended Articles”). 
  

	 	(a)	 Drag-Along Right. 

If Shareholders holding Shares representing at least 61% of the outstanding Shares (the “Selling Shareholders”) irrevocably agree to
Transfer (as defined in the Amended Articles) to one or more Persons (as defined in the Amended Articles) acting as principal and who is or are independent of the Selling Shareholders (a “Purchaser”) all or some portion of the Shares held
or beneficially owned by the Selling Shareholders (collectively, the “Offered Securities”) pursuant to a bona fide offer, agreement or Deemed Liquidation Event (collectively, a “Purchase Offer”) from or with the Purchaser, the
Selling Shareholders shall have the right (the “Drag-Along Right”), but not the obligation, to require each of the other holders or beneficial owners of Shares (the “Other Securityholders”) to sell the same proportion of Shares
of the Company beneficially owned by such Other Securityholders as is being sold by the Selling Shareholders (collectively, the “Drag-Along Securities”) to the Purchaser for an amount and on the terms and conditions set out in this section
3.4 and in accordance with Article 27 of the Amended Articles, provided for greater certainty, notwithstanding this section 3.4(a), in no event shall the Other Securityholders be required to sell any fractional Shares and in the event that the
proportion of Shares required to be sold by any Other Securityholder pursuant to this section 3.4(a) includes a fractional share, such 

  
 C-6 

 
number of Shares required to be sold by such Other Securityholder shall be rounded down to the nearest whole number. 
  

	 	(b)	 Voting. 

If any transaction or series of transactions contemplated in this section 3.4 requires shareholder or securityholder approval, each Shareholder
that is required to sell Shares pursuant to this section 3.4 will participate fully in any such purchase and vote, or cause to be voted (in person, by proxy or by action by written consent, if applicable) all Shares held or beneficially owned by, or
over which such holder exercises voting control or direction, in favour of, and to approve and adopt, as applicable, such transaction or transactions and all actions as may be necessary in connection therewith, including, if applicable, any required
or related amendment to the notice of articles of the Company or the Amended Articles. 
  

	 	(c)	 Other Restrictions. 

No Shareholder that may be required to sell Shares pursuant to this section 3.4 shall deposit, or permit any of their Affiliates to deposit,
except as provided in this section 3.4 and in accordance with Article 27 of the Amended Articles, any Shares beneficially owned by such holder or Affiliate in any voting trust or subject any Shares to any agreement or arrangement with respect to the
voting of such securities (other than proxies that may be granted from time to time in respect of specific meetings), unless specifically requested to do so by the Purchaser in connection with a sale pursuant to this section 3.4. 

 

	 	(d)	 Acknowledgement of Article 27.  

Each Shareholder confirms and acknowledges that any Purchase Offer made and Drag Along Right exercised under this section 3.4 is subject to and
shall be made in accordance with the terms and conditions of Article 27 of the Amended Articles. 
  

	3.5	 Company’s Option to Repurchase Shareholder’s Shares 

In the event that a Shareholder becomes at any time employed, either directly or indirectly, with a Competitive Business, then at any time during the year
following the date on which the Company becomes aware of the Shareholder’s employment with a Competitive Business, the Company may, in its sole discretion, repurchase all of the Shares held by the Shareholder on payment of the Repurchase Price
for each Share to be repurchased together with all declared and unpaid dividends thereon. In the case of such repurchase, the Company will provide the Shareholder with not less than 30 days’ written notice of such repurchase by delivering a
notice (the “Repurchase Notice”) to the Shareholder, specifying the date and place of repurchase, the Repurchase Price and the number of Shares to be repurchased. If a Repurchase Notice is delivered to the Shareholder by the Company
and the Company deposits sufficient funds to repurchase the Shares in an account at a lending institution identified in the Repurchase Notice on or before the proposed date of repurchase, the Shares to be repurchased will be deemed to be repurchased
and the Shareholder will have no further rights in respect thereof, except to receive the payment out of the funds so deposited by the Company. 
  

	3.6	 Going Public Agreements 

If the Company proceeds to list any shares of the Company on a public stock exchange or commences a public offering, each holder of an Option granted under
the Plan will promptly enter into all such escrow, 

  
 C-7 

 
pooling or other agreements as are required by the securities regulatory authorities, the exchange, the agents or the underwriters in connection with such listing or public offering. 

 

	3.7	 Recognition of Transfers 

The Company will not recognize any Transfers of Shares made in violation of this Agreement. 

 

	3.8	 Endorsement on Share Certificates 

Any and all certificates representing Shares now or hereafter owned by the Shareholder during the currency of this Agreement (whether such Shares are issued
initially or with respect to Transfer or otherwise) will have endorsed thereon in bold type the following legend: 
 “The securities represented by
this certificate are subject to the provisions of an Agreement dated for reference the ● day of●, 201●, as amended from time to time, and such securities are not transferable on the books
of the Company except in accordance and compliance with the terms and conditions of such Agreement.” 
 ARTICLE 4 

GENERAL PROVISIONS 
  

	4.1	 No Partnership 

Nothing in this Agreement or in the relationship of the parties hereto will be construed as in any sense creating a partnership among or between the parties
or as giving to any party any of the rights or subjecting any party to any of the creditors of the other party. 
  

	4.2	 Time of the Essence 

Time will be of the essence of this Agreement. 
  

	4.3	 Further Acts 

Each of the parties to this Agreement will at the request of any other party, and at the expense of the Company, execute and deliver any further documents and
do all acts and things as that party may reasonably require in order to carry out the true intent and meaning of this Agreement. 
  

	4.4	 Parties of Interest 

This Agreement and the rights of such party hereunder will enure to the benefit of and be binding upon the parties hereto, their permitted assigns and their
personal representatives, administrators, heirs and successors. 
  

	4.5	 Share Reorganizations 

The provisions of this Agreement relating to Shares will also apply, with the necessary changes, to the following: 

 

	 	(a)	 any shares or securities into which such Shares may be converted, changed, reclassified, redivided,
redesignated, redeemed, subdivided or consolidated; 

  
 C-8 

	 	(b)	 any shares or securities that are received by the Shareholder as a stock dividend or distribution payable in
shares of the Company; and 

  

	 	(c)	 any shares or securities of the Company or of any successor or continuing corporation to the Company that may
be received by the Shareholder on a reorganization, amalgamation, consolidation, merger or otherwise. 

  

	4.6	 Governing Law 

This Agreement will be exclusively construed and governed by the laws in force in British Columbia and the laws of Canada applicable thereto and, except as
provided in section 4.12, the courts of British Columbia (and the Supreme Court of Canada, if necessary) will have exclusive jurisdiction to hear and determine all disputes arising hereunder. Except as provided in section 4.12, each of the
parties hereto irrevocably attorns to the jurisdiction of said courts and consents to the commencement of proceedings in such courts. This section 4.6 will not be construed to affect the rights of a party to enforce a judgment or award outside
said province, including the right to record and enforce a judgment or award in any other jurisdiction. 
  

	4.7	 Entire Agreement 

This Agreement constitutes the entire agreement between the parties to this Agreement with respect to the subject matter hereof and supersedes all prior
negotiations, proposals and agreements, whether oral or written, with respect to the subject matter of this Agreement. 
  

	4.8	 Notices 

All notices, demands and payments under this Agreement must be in writing and may be delivered personally or by facsimile transmission to the addresses as
first written above and on any document pursuant to which a Person becomes party hereto or such other addresses as may from time to time be notified in writing by the parties. All notices will be deemed to have been given and received on the next
business day following the date of transmission or delivery, as the case may be. 
  

	4.9	 Waiver 

Failure by any party hereto to insist in any one or more instances upon the strict performance of any one of the covenants contained herein will not be
construed as a waiver or relinquishment of such covenant. No waiver by any party hereto of any such covenant will be deemed to have been made unless expressed in writing and signed by the waiving party. 

 

	4.10	 Severability 

The unlawfulness or invalidity or unenforceability of any provision in this Agreement or of any covenant herein contained on the part of any party will not
affect the validity or enforceability of any other provision or covenant hereof or herein contained and the parties hereby undertake to renegotiate in good faith, with a view to concluding arrangements as nearly as possible the same as those herein
contained. 
  

	4.11	 Assignment 

No party will be entitled to assign his or her rights under this Agreement to any Person without the prior written consent of the other parties, provided that
such consent will not be unreasonably withheld. 

  
 C-9 

	4.12	 Arbitration 

In the event of a dispute hereunder which does not involve a party seeking a court injunction, that dispute will promptly be referred to and finally resolved
by arbitration administered by the British Columbia International Commercial Arbitration Centre in accordance with its rules. The place of arbitration will be Vancouver, British Columbia. 

 

	4.13	 Counterparts 

This Agreement may be executed in several counterparts (including by fax), each of which when so executed will be deemed to be an original and will have the
same force and effect as an original but such counterparts together will constitute but one and the same instrument. 
 IN WITNESS WHEREOF the parties have
executed this Agreement as of the date first written above. 
  

			
	GENOMEDX BIOSCIENCES INC.
		
	 Per:
	 	 
		 	 Administrator, Stock Option Plan
 GenomeDx
Biosciences Inc.

  

					
	SIGNED, SEALED AND DELIVERED by ● in the presence of:	  	 )
 )
	  	
	___________________________________________	  	)	  	
	Signature	  	)	  	
	___________________________________________	  	)	  	___________________________________________
	 Print Name
	  	 )
 )
	  	Print Name:
	___________________________________________	  	)	  	
	Address	  	 )
 )
	  	
	___________________________________________	  	)	  	
	Occupation	  	)	  	
	(witness as to all signatures)	  	)	  	

  
 C-10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]